Antihypertensive Drug News and Research

RSS

Hypertension in the very elderly trial stopped

An international trial looking at the benefits of giving blood-pressure lowering medication to elderly patients has stopped early, after researchers observed significant reductions in overall mortality in those receiving treatment.

7 Aug 2007

Ranbaxy receives approval to manufacture and market Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has announced that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

11 Jul 2007

Drug costs cut in Norway following new rule on prescribing

Research in Norway has shown that there have been substantial savings in drug costs since the introduction of a regulation requiring doctors to prescribe the recommended first-line treatment for hypertension (high blood pressure).

9 Jul 2007

Ranbaxy receives tentative approval to manufacture Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

23 Jun 2007

Review of six large-scale clinical trials of aliskiren

Hypertension is a serious condition affecting millions.Currently there are seven classes of drugs used to reduce blood pressure. Aliskiren (Tekturna , Rasilez) is the first of a new class of orally active antihypertensive drugs that works by inhibiting renin.

10 May 2007

Traditional African medicines may hold potential for treating high blood pressure

Medicinal plants are an integral part of African culture, one of the oldest and most diverse in the world.

2 May 2007

Risedronate versus Alendronate study

The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal.

3 Apr 2007

Beta-blockers should not be a doctor's first choice for treating high blood pressure

Beta-blocker drugs such as Tenormin, Inderal and Lopressor should not be a doctor's first choice for treating high blood pressure, according to a large new review of studies.

20 Feb 2007

Ranbaxy granted approval to manufacture Atenolol

Ranbaxy Laboratories has announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Atenolol Tablets USP, 25 mg, 50 mg, and 100 mg.

2 Jan 2007

Study shows Diovan reduced urinary protein excretion in patients with type 2 diabetes and high blood pressure

In patients with high blood pressure and type 2 diabetes, the blood pressure-lowering medication Diovan (valsartan) significantly reduced urinary protein excretion, with high doses providing the greatest sustained reduction , according to data presented at the Amer ican Heart Association's (AHA) Annual Scientific Sessions.

13 Nov 2006

NicOx announces EMEA approval of Naproxcinod study plan

NicOx S.A today announced that it has received scientific advice on its proposed phase 3 clinical plan for naproxcinod (HCT 3012) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).

17 Oct 2006

Adopting multiple healthy habits may significantly lower risk of coronary heart disease in men

A prospective study of 42,847 middle-aged and older U.S. men participating in the Health Professionals Follow-up Study has found that a healthy lifestyle is associated with a lower risk of coronary heart disease (CHD), even among men taking antihypertensive or lipid-lowering medications.

5 Jul 2006

When it comes to diabetes doctors failing to follow 'doctors orders'

According to the latest reports when it comes to diabetes and following doctors orders, doctors are failing their patients.

12 Jun 2006

Prostate drug doxazosin blocks receptor in heart muscle, increasing risk of heart failure

Doxazosin, a drug commonly prescribed to help improve urinary flow in men with enlarged prostates, increases the likelihood of heart failure by blocking specific receptors in heart muscle cells, according to a study conducted at the San Francisco VA Medical Center.

4 Apr 2006

Shape and function of the heart improves with apnea treatment

Patients with obstructive sleep apnea have enlarged and thickened hearts that pump less effectively, but the heart abnormalities improve with use of a device that helps patients breathe better during sleep, according to a new study in the April 4, 2006, issue of the Journal of the American College of Cardiology.

4 Apr 2006

High blood pressure declines and remains low after bariatric surgery

The prevalence of hypertension (high blood pressure) appears to decline and remain low after bariatric surgery, and blood pressure drops the most among patients who had untreated hypertension before the procedure, according to a study in the March issue of Archives of Surgery.

21 Mar 2006

Diabetics benefit less from anti-hypertensive treatment to reduce enlarged heart

Standard blood-pressure-lowering treatment to reduce dangerously enlarged hearts is much less effective and less beneficial in diabetic vs. nondiabetic patients, a team led by NewYork-Presbyterian Hospital/Weill Cornell Medical Center researchers reports in this month's issue of Circulation.

20 Mar 2006